Ultragenyx Pharmaceutical Inc 10-Q for FY2026 Q3
Ultragenyx Pharmaceutical Inc. (RARE)
10-Q
2026-11-04
For: 2026-09-30
View Original
Added on
November 04, 2026
About this 10-Q
Ultragenyx Pharmaceutical Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Ultragenyx Pharmaceutical Inc. reported $523 million in nine-month revenue and $401 million in available cash as of September 30, 2026. GENGLYCOS and FAYUVI received FDA approvals, and the company expects $349 million in combined net PRV proceeds. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $173M
- up 8.1% from $160M a year earlier
- Net loss
- $118M
- compared with a net loss of $180M a year earlier
- Diluted EPS
- -$1.16
- compared with -$1.81 a year earlier